Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  von Otter, Malin ^a   Landgren, Sara ^a   Nilsson, Staffan ^b   Celojevic, Dragana ^a   Bergström, Petra ^a   Håkansson, Anna ^a   Nissbrandt, Hans ^a   Drozdzik, Marek ^c   Bialecka, Monika ^c   Kurzawski, Mateusz ^c   Blennow, Kaj ^a   Nilsson, Michael ^a   Hammarsten, Ola ^a   Zetterberg, Henrik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; POLAND; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; GENETICS; HAPLOTYPE; MIDDLE AGED;

AGED; CASE-CONTROL STUDIES; FEMALE; HAPLOTYPES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77951176535     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-36     Document Type: Article

References (39)

1. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 2008, 1147:93-104. 2745097, 19076434.
2. Kedar NP. Can we prevent Parkinson's and Alzheimer's disease?. J Postgrad Med 2003, 49(3):236-245.
3. Nunomura A, Moreira PI, Lee HG, Zhu X, Castellani RJ, Smith MA, Perry G. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Targets 2007, 6(6):411-423. 10.2174/187152707783399201, 18220780.
4. Chinta SJ, Andersen JK. Redox imbalance in Parkinson's disease. Biochim Biophys Acta 2008, 1780(11):1362-1367. 2547405, 18358848.
5. Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 2006, 6(1):37-46. 10.1007/s11910-996-0008-9, 16469270.
6. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299(5604):256-259. 10.1126/science.1077209, 12446870.
7. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007, 47:89-116. 10.1146/annurev.pharmtox.46.120604.141046, 16968214.
8. Dhakshinamoorthy S, Jaiswal AK. Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. Oncogene 2001, 20(29):3906-3917. 10.1038/sj.onc.1204506, 11439354.
9. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999, 13(1):76-86. 10.1101/gad.13.1.76, 316370, 9887101.
10. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 2004, 24(19):8477-8486. 10.1128/MCB.24.19.8477-8486.2004, 516753, 15367669.
11. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 2005, 25(1):162-171. 10.1128/MCB.25.1.162-171.2005, 538799, 15601839.
12. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004, 24(16):7130-7139. 10.1128/MCB.24.16.7130-7139.2004, 479737, 15282312.
13. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004, 24(24):10941-10953. 10.1128/MCB.24.24.10941-10953.2004, 533977, 15572695.
14. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, Yamamoto M. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol 2006, 26(1):221-229. 10.1128/MCB.26.1.221-229.2006, 1317630, 16354693.
15. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997, 236(2):313-322. 10.1006/bbrc.1997.6943, 9240432.
16. Wild AC, Moinova HR, Mulcahy RT. Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J Biol Chem 1999, 274(47):33627-33636. 10.1074/jbc.274.47.33627, 10559251.
17. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 1996, 93(25):14960-14965. 10.1073/pnas.93.25.14960, 26245, 8962164.
18. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 1999, 274(37):26071-26078. 10.1074/jbc.274.37.26071, 10473555.
19. Vargas MR, Pehar M, Cassina P, Beckman JS, Barbeito L. Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR-dependent motor neuron apoptosis. J Neurochem 2006, 97(3):687-696. 10.1111/j.1471-4159.2006.03742.x, 16524372.
20. Kraft AD, Johnson DA, Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 2004, 24(5):1101-1112. 10.1523/JNEUROSCI.3817-03.2004, 14762128.
21. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 2003, 23(8):3394-3406.
22. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci USA 2005, 102(1):244-249. 10.1073/pnas.0408487101, 538748, 15611470.
23. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 2008, 28(50):13574-13581. 10.1523/JNEUROSCI.4099-08.2008, 19074031.
24. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 2007, 66(1):75-85. 10.1097/nen.0b013e31802d6da9, 2253896, 17204939.
25. Siebert A, Desai V, Chandrasekaran K, Fiskum G, Jafri MS. Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. J Neurosci Res 2009, 87(7):1659-1669. 10.1002/jnr.21975, 19125416.
26. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 2006, 103(41):15091-15096. 10.1073/pnas.0607260103, 1586179,1586179, 17015834.
27. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci USA 2009, 106(8):2933-2938. 10.1073/pnas.0813361106, 2650368, 19196989.
28. Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y, Nagai Y, Oka A, Inoko H, Fukae J, Saito Y, Sawabe M, Murayama S, Yamamoto M, Hattori N, Murata M, Toda T. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 2006, 15(7):1151-1158. 10.1093/hmg/ddl030, 16500997.
29. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993, 39:165-172.
30. Westerlund M, Belin AC, Anvret A, Hakansson A, Nissbrandt H, Lind C, Sydow O, Olson L, Galter D. Cerebellar alpha-synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. FASEB J 2008, 22(10):3509-3514. 10.1096/fj.08-110148, 18606870.
31. Bergman O, Hakansson A, Westberg L, Nordenstrom K, Carmine Belin A, Sydow O, Olson L, Holmberg B, Eriksson E, Nissbrandt H. PITX3 polymorphism is associated with early onset Parkinson's disease. Neurobiol Aging 31(1):114-117. 10.1016/j.neurobiolaging.2008.03.008, 18420308.
32. The HapMap Consortium The International HapMap Project. Nature 2003, 426(6968):789-796. 10.1038/nature02168, 14685227, The HapMap Consortium.
33. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265. 10.1093/bioinformatics/bth457, 15297300.
34. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science 2002, 296(5576):2225-2229. 10.1126/science.1069424, 12029063.
35. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999, 14(5-6):143-149.
36. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995, 12(5):921-927.
37. Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, Aplenc R, Yamamoto T, Yamamoto M, Cho HY, Kleeberger SR. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J 2007, 21(9):2237-2246. 10.1096/fj.06-7759com, 17384144.
38. Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, Pant PV, Frazer KA, Cox DR, Ballinger DG. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005, 77(5):685-693. 10.1086/496902, 1271381, 16252231.
39. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002, 30(17):3894-3900. 10.1093/nar/gkf493, 137415, 12202775.